If you are looking for ways to communicate with researchers that identify themselves as immunology researchers, some of Percepta’s latest data suggests the popularity of various information sources spans a pretty broad spectrum. Search engines still rank high as a place immunologist look for product information. Also popular are peer recommendations, journal citations and company web sites, with more…

As has been shown again and again, seemingly homogeneous cell populations often consist of more than one cell type, which can confound research results. Single-cell research offers a bottom-up approach to circumventing such unwanted cellular heterogeneity. As a testament to its potential promise, the NIH has committed ~$90 million over 5 years to single cell analysis research. At Percepta,…

In February 2013 we polled our panel of fluorescent imaging reagent users regarding their anticipated laboratory budget. Data reveals that commercial users anticipate a slight increase compared to academic users. As shown in the table, 24.1% of commercial users of fluorescent imaging reagents expect their budget to increase over the next 12 months, vs. 17.6% of academic users (a…

If you thought cell therapy had suffered too many setbacks in recent years and was stuck in neutral – think again. In a recent Percepta poll of 250 randomly selected life science researchers working in biotechnology and pharmaceutical companies more than 20% are involved in projects focused on allogeneic or autologous cell therapy and/or regenerative medicine. Even more surprising…

It was a hectic close to 2010 which shows us that biotools industry is alive and healthy! Though the future economic environment for the globe remains uncertain and public funding levels for life sciences in the US may plataue of or even dip in 2011, there were several things that we noticed at Percepta that we believe will be…

In the recent few quarters Percepta has experienced an increase in demand for studies relating to better serving the pharmaceutical industry. The focus of the studies have varied considerably but the trend is evident. This tells us bio-tools companies are getting more serious about tailoring an offering to the drug discovery and development market that will resonate with the…

What will be the next big thing to drive growth in the bio-tools industry? Will it be epigenetics? Gene regulation is now a focus of many drug development programs within the pharmaceutical industry. The past five years have seen the genesis of many new companies dedicating their focus to products and services tailored to monitoring gene regulation by methylation,…

We hear all the time that elements of traditional molecular biology reagent portfolios have become increasingly commoditized. Dictionary.com defines commodity as “any bulk good traded in an exchange…”. By that people generally mean that the reagent is not differentiated by anything other than price. One bag of tips or tubes is the same as the next so why pay…

We see it over and over again. Large bio-tools companies are often cited in surveys by market research participants as the suppliers of research products that they don’t even sell. What is this telling us? The cynical might think it means researchers are just clicking on buttons to get to the end of the survey – and we know…

Did you realize recently that the 1st quarter is over and you have not hit the revenue target? If so, do you know why the company missed the number? If you don’t know – is that your problem? Is it someone else’ problem?

What is the plan? Is it panic time or do you know the next steps? Does your…